Sanofi Pasteur Biologics, LLC

Acambis Inc.

Hookipa Biotech Gmbh

Sanofi Pasteur Biologics Co.

Other

Saint Louis University

Oravax, Inc.

Natural Environment Research Council

Oravax-merieux Co.

Farshad Guirakhoo

Thomas P Monath

Konstantin V Pugachev

Juan Arroyo

Harold Kleanthous

Simon Delagrave

Alexander A Rumyantsev

Karen Lingnau

Katherine Cohen

Klaus Orlinger

Gerhard Fuhrmann

Elizabeth Watson

Andreas Aspöck

Bettina Kiefmann

John Avram Catalan

Vera Baumgartl-Strasser

Mario Aistleithner

Jacques Pappo

Katharina Bayer

Elsa Mühlbacher

Nathan Brown

J Jian Liu

Thomas J Chambers

Manuela Kainer

Bernhard Brim

Jian Liu

Samuel K Ackerman

Richard A Weltzin

Cynthia K Lee

Polly Roy

Hitesh Bhagat

Gopalan Soman

William D Thomas

Richard D Nichols, Jr

Thomas H Ermak

Ilene Sussman

Thomas Ermak

Caroline Maier

Andreas Aspock

Elsa Muhlbacher

John A Catalan

Thomas Monath

Andreas ASPÖCK

Elsa MÜHLBACHER

Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.

CMV vaccines

The invention provides flavivirus vaccines and methods of making and using these vaccines.

Flavivirus vaccines

This invention relates to bicistronic flavivirus vectors, methods of using such vectors in the prevention and treatment of disease, and methods of making such vectors.

Recombinant bicistronic flavivirus vectors

The invention provides recombinant flavivirus vaccines that can be used in the prevention and treatment of flavivirus infection. The vaccines of the invention contain recombinant flaviviruses including attenuating mutations.

[object Object]

The invention provides attenuated Flavivirus vaccines, such as vaccines against Japanese encephalitis virus and West Nile virus, as well as methods of making and using these vaccines.

Vaccines against japanese encephalitis virus and west nile virus

This invention relates to chimeric flavivirus vectors that can be used, for example, in the prevention and treatment of influenza virus infection, compositions including such viral vectors, and methods employing the vectors.

Flavivirus vaccine vector against influenza virus

Recombinant flavivirus vaccines

The invention provides attenuatedvaccines, such as vaccines against Japanese encephalitis virus and West Nile virus, as well as methods of making and using these vaccines.

Vaccines against Japanese encephalitis virus and West Nile virus

Chimeric flaviviruses

A chimeric live, infectious, attenuated virus containing a yellow fever virus, in which the nucleotide sequence for a prM-E protein is either deleted, truncated, or mutated, so that functional prM-E protein is not expressed, and integrated into the genome of the yellow fever virus, a nucleotide sequence encoding a prM-E protein of a second, different flavivirus, so that the prM-E protein of the second flavivirus is expressed.

Chimeric flavivirus vaccines

Methods and compositions are provided for prophylactic and antibacterial therapy for Helicobacter, particularly for Helicobacter pylori, infection of humans. The immunogenic composition of the invention is composed of a plurality of multimeric complexes, each complex being composed of recombinant, enzymatically inactive Helicobacter pylori urease. Each multimeric complex is composed of six Urease A subunits and six Urease B subunits. Alternatively, the composition is composed of a mixture of multimeric complexes, wherein each multimeric complex in the mixture is composed of six Urease A subunits and six Urease B subunits or four Urease A subunits and four Urease B subunits.

Multimeric, recombinant urease vaccine

Growing community of inventors

Melrose, MA, United States of America

Farshad Guirakhoo